Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, ...

TechneLite. Rounding out Lantheus’ meaningful contributors to its top line is TechneLite, a generator of technetium, a ...

BEDFORD, Mass. - Lantheus Holdings, Inc. (NASDAQ: LNTH), a leader in the radiopharmaceutical industry, announced today the completion of its acquisition of Evergreen Theragnostics, Inc., a ...

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics.

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.